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Abstract
The effector function of natural killer (NK) cells is modulated by surface expression of
a range of killer-cell immunoglobulin-like receptors (KIRs) that interact with human
leukocyte antigen (HLA) class I ligands. We describe the use of real-time polymerase
chain reaction (PCR) assays that allow easy and quick detection of 16 KIR genes
and the presence/absence of KIR-ligands based on allelic discrimination at codon
80 in the HLA-A/B Bw4 and HLA-C C1/C2 genes. These methods overcome the
tedious and expensive nature of conventional KIR genotyping and HLA class I typing
using sequence-specific primer (SSP) PCR, sequence-specific oligonucleotide (SSO)
hybridization or sequence-based typing (SBT). Using these two cost-effective assays,
we measured the frequencies of KIRs, KIR-ligands and KIR/KIR-ligand pairs in a
cohort of Black women recruited in South Africa.
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Introduction
Natural killer (NK) cells comprise approximately 10%–15%
of peripheral blood lymphocytes, and their primary function is
the detection and destruction of malignant and virus-infected
cells (1, 2). A number of cell surface receptors that control the
effector function of NK cells have been characterized, such as
the killer-cell immunoglobulin-like receptors (KIRs), C-type
lectins and natural cytotoxicity receptors (NCRs) (3, 4).
KIR proteins are encoded in the leukocyte receptor complex
(LRC) located on chromosome 19, and are characterized by
the presence of two-dimensional (2D) or three-dimensional
(3D) extracellular immunoglobulin-like domains that deter-
mine ligand specificity (3, 5). In addition, KIRs fall into two
broad groups with different cytoplasmic tail lengths. Recep-
tors with long tails (L) suppress NK cell activation, whereas
short-tail (S) receptors are stimulatory, inducing the secre-
tion of interferon-γ (IFN-γ) and the release of perforin and
granzyme (6).
Sixteen KIR genes have been identified; 7 are inhibitory
(KIR2DL1-3, KIR2DL5, KIR3DL1-3 ), 6 are activating (KIR
2DS1-5 and KIR3DS1 ), 2 are pseudogenes (KIR2DP1 and
KIR3DP1 ) (5, 7) and 1 has both inhibitory and activating
potential (KIR2DL4 ) (8). Certain KIRs, upon engagement
with specific human leukocyte antigen (HLA) class I ligands,
may either inhibit or stimulate NK cell activity (6, 9). HLA
and KIR genes are highly polymorphic and map to chromo-
somes 6 and 19, respectively, and thus assort independently.
On the basis of KIR gene combinations, two haplotype groups
have been identified; haplotype A, with a fixed content of nine
KIR genes (KIR2DL1/3/4, KIR3DL1-3, KIR2DS4, KIR2DP1
and KIR3DP1 ) and haplotype B, with variable gene content.
Collectively, this allows for a large range of KIR/HLA diver-
sity (10).
KIR-HLA ligands (KIR-ligands) for KIR2DL1-3, KIR2DS1
and KIR2DS4 are HLA-C molecules. KIR2DL2 and KIR2DL3
recognize HLA-C group 1 (C1) allotypes, which have an
asparagine at position 80 (C1:N80), whereas KIR2DL1 and
KIR2DS1 bind to the HLA-C group 2 (C2) allotypes, which
have a lysine at position 80 (C2:K80) (11). Whilst KIR2DS4
can bind to both subsets of HLA-C C1 and C2 allotypes, it has
also been found to bind to two HLA-A alleles (HLA-A*11:01
and A*11:02) (12). For KIR3DL1 and putatively KIR3DS1,
the ligands are HLA-B allotypes with the Bw4 motif desig-
nated by five variable amino acids spanning positions 77–83,
with either isoleucine (Bw4:I80) or threonine (Bw4:T80) at
position 80 (13, 14). In addition, HLA-B Bw4:T80 variants
can vary with alanine (Bw4:T80A81) or leucine (Bw4:T80L81)
at position 81 (13–15). Some HLA-A allotypes also have
the Bw4 motif (Bw4:I80) and bind KIR3DL1 and putatively
KIR3DS1, whereas HLA-A allotypes lacking the Bw4 motif
(non-Bw4:T80) and HLA-B Bw6 allotypes (Bw6:N80) are not
known to bind any KIRs.
Specific KIR and KIR-ligand combinations have been
associated with numerous infectious/autoimmune disease
outcomes as well as in pregnancy and transplantation
complications (10, 16). The presence of specific KIRs with or
without their corresponding ligands can influence susceptibility
to disease and/or improved response to therapy (10, 17–19).
Conventional KIR genotyping is done by sequence-specific
primer polymerase chain reaction (SSP-PCR), and HLA class
I typing is done by SSP-PCR, sequence-specific oligonu-
cleotide (SSO) hybridization or sequence-based typing (SBT)
assays. These methods are often cumbersome and expensive
and require large quantities of high-quality genomic DNA.
Amplified SSP products are visualized by agarose gel elec-
trophoresis, which is time-consuming as well as hazardous if
using ethidium bromide staining (16).
We have optimized and validated two real-time PCR
assays for KIR genotyping and identification of KIR-ligands
using samples previously characterized by SSP-PCR and
SBT. The KIR genotyping assay is able to determine the
presence/absence of 16 KIR genes, while the KIR-ligand assay
identifies the presence/absence of KIR-ligands (HLA-A/B
Bw4, and HLA-C C1/C2). We then applied these new
methods to identify KIR genotype, KIR-ligand frequencies and
KIR/KIR-ligand pairs in a small South African cohort.
Methodology
Validation samples
Stored genomic DNA was available for 230 samples previ-
ously genotyped for KIR or HLA class I using commercial
assays. The real-time PCR KIR genotyping assay was val-
idated against 50 samples, consisting of 24 South African
Black individuals and 26 Caucasians that were KIR genotyped
by SSP-PCR. Importantly, all 16 KIR genes were represented
in these samples. The real-time PCR KIR-ligand assay was
validated against 220 samples that had been HLA typed by
SBT, in which all variants at position 80 were represented. To
accommodate HLA class I allelic variation, we tested samples
from South African Black individuals (n = 107) and Cau-
casians (n = 83), as well as published HLA-A, -B and -C
reference samples (n = 30) obtained from the International
Histocompatibility Working Group (http://www.ihwg.org).
Study samples
Whole-blood ethylenediaminetetraacetic acid (EDTA) sam-
ples were collected from consenting Black women (n = 81)
recruited from the Carletonville mining area, South Africa.
A salting-out method (20) was used to extract genomic DNA
from leukocytes isolated from 1 ml of whole blood. DNA
concentration was measured on a nanodrop spectrophotome-
ter (Thermo Scientific, Wilmington, MA). The study was
approved by the Human Research Ethics Committee (Medical)
at the University of the Witwatersrand and informed written
consent was obtained from all participants.
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KIR PCR primers and real-time PCR
To date, real-time PCR-based KIR genotyping and HLA
KIR-ligand identification assays have been described by
Alves et al. (21) and Koehler et al. (22). In our system,
we wished to avoid the use of fluorescent probe chemistry
and nested PCR methods used by Koehler et al. (22) in
favor of SYBR green chemistry. For our real-time KIR
genotyping assay, we selected previously published KIR
primer sequences (16, 21, 23), which we mapped to updated
KIR gene alignments in the Immuno Polymorphism Database
(IPD) database (24). A combination of primers was used to
improve detection of KIR allelic variants, with the exception
of KIR2DL3 and KIR3DP1, where a single primer set
was used (Table 1). The KIR2DL3 primer set detects all
known alleles; however, the pseudogene KIR3DP1 primer
set does not detect KIR3DP1*004 and KIR3DP1*009 alleles.
Furthermore, an internal control gene galactosylceramidase
(GALC ) (21) was included.
For real-time PCR amplification, each 5-μl reaction con-
tained 2× SYBR Green master mix (Roche, Mannheim,
Germany), 0.2 μM KIR-specific primers, 0.2 μM GALC-
specific primers and 5 ng of genomic DNA. PCR cycling
was performed in a 96-well format on an ABI PRISM 7500
real-time instrument (Applied Biosystems, Foster City, CA)
as follows: 10 min at 95◦C, 30 cycles of 15 s at 95◦C and 1
min at 60◦C. Melt curve analysis was performed after cycling
(Figure 1A) and could discriminate between GALC (Tm =
74.89◦C) and the KIR amplicons (Tm = 78.5.5◦C–85.9◦C),
thereby making it simple to identify the presence/absence of
specific KIR genes. The presence of an internal control ampli-
con ensured that the absence of a KIR amplicon was a true
result.
KIR-ligand primers and real-time PCR
We designed our KIR-ligand primers from HLA class I
alignments available at the International Immunogenetics
Project (IMGT)/HLA database (25) to discriminate Bw4 from
Bw6 allotypes at codon 80. Primers were synthesized with 3′
locked nucleic acid (LNA) bases (Exiqon, Vedbaek, Denmark)
in order to increase template specificity (Table 2). Each PCR
included an internal positive control gene albumin (ALB) (26).
For real-time PCR amplification, each 5-μl reaction con-
tained 2× SYBR Green master mix (Roche), 0.2 μM KIR-
specific primers, 0.2 μM ALB-specific primers and 5 ng of
genomic DNA. PCR cycling was performed in a 96-well for-
mat on an ABI PRISM 7500 real-time instrument (Applied
Biosystems) as follows: 10 min at 95◦C, 30 cycles of 15 s at
95◦C, 5 s at 60◦C and 1 min at 72◦C. Melt curve analysis was
performed after cycling (Figure 1B), and similar to the KIR
assay, differences in melting temperature could discriminate
between ALB (Tm = 75.62◦C) and the KIR-ligand amplicons
(Tm = 87.3◦C–88.3◦C).
High-resolution HLA typing
High-resolution (four-digit) HLA typing was performed on
validation samples as follows: DNA was extracted from
either peripheral blood mononuclear cells or granulocytes
using the Pel-Freez DNA isolation kit (Dynal Biotech, Ullern-
chausseen, Norway). HLA-A, -B and -C typing was performed
by DNA sequencing of exons 2, 3 and 4 using SBTexcellerator
kits (Qiagen, Dusseldorf, Germany) on an ABI3100 Genetic
Analyzer (Applied Biosystems) and assign-sbt v3.5 soft-
ware (Conexio Genomics, Fremantle, Western Australia). Any
ambiguities resulting from either polymorphisms outside the
sequenced exons or identical heterozygote combinations were
resolved using statistical methods (27).
SSP-PCR KIR genotyping
KIR genotyping was performed on validation samples using
either a commercially available kit, sequence-specific primer
KIR PCR genotyping kit (Olerup, Loewengasse, Austria) or
a published protocol (16). These methods both detect the
presence/absence of the following 16 KIR genes: KIR2DL1-5,
KIR2DS1-5, KIR3DL1-3, KIR3DS1, KIR2DP1 and KIR3DP1.
On the basis of individual KIR gene combinations, two
genotype groups were stratified, the AA genotype with nine
genes (KIR2DL1/3/4, KIR3DL1-3, KIR2DS4, KIR2DP1 and
KIR3DP1 ) and the Bx genotype, which can be a mixture of
AB or BB haplotypes. In addition, KIR Bx genotype numbers
were assigned according to published nomenclature on the
Allele Frequencies database (28).
Data analysis
For both sets of data (SSP-PCR, SBT and real-time PCR),
carrier frequencies for the observed KIR and KIR-ligands
were determined by direct counting (individuals positive
for the gene divided by the individuals tested per popula-
tion × 100). Real-time PCR KIR and KIR-ligand assays were
validated by direct comparison with SBT- and SSP-PCR-
based typing results of the same samples.
Results
Validation of real-time PCR KIR assay
Using samples that represented the full spectrum of the
KIR genes, we tested real-time PCR KIR assay on the KIR
validation samples (n = 50) and compared our results to
the gel-based (SSP-PCR) KIR genotyping kit (Olerup) and
published methods (16). We found the real-time PCR KIR
assay was 100% concordant with conventional SSP-PCR
methods (Table 3).
Validation of real-time PCR KIR-ligand assay
In comparison with the commercial high-resolution SBT
method, the real-time KIR-ligand assay correctly genotyped
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Table 1 PCR primer sets used for real-time KIR genotyping assay
KIR gene
PCR well
no. Primers Sequences (5′ –3′)
Primer
binding site Product Tm (
◦C) Alleles not detected
2DL1 1 F1a GTTGGTCAGATGTCATGTTTGAA Exon 4 80.36 —
R1a GGTCCCTGCCAGGTCTTGCG Exon 4
2 F1a TGGACCAAGAGTCTGCAGGA Exon 8 82.12 KIR2DL1*005
R1a TGTTGTCTCCCTAGAAGACG 3′UTR
2DL2 3 F1a CTGGCCCACCCAGGTCG Exon 4 80.68 KIR2DL2*004, *00601,
*00602, *00303, *004
R1a GGACCGATGGAGAAGTTGGCT Exon 4
4 F1b AAACCTTCTCTCTCAGCCCA Exon 5 83.30 KIR2DL2*009
R1b GCCCTGCAGAGAACCTACA Exon 5
2DL3 5 Fb AGACCCTCAGGAGGTGA Exon 9 79.47 —
Rb CAGGAGACAACTTTGGATCA Exon 9
2DL4 6 F1a CAGGACAAGCCCTTCTGC Exon 3 78.08 —
R1a CTGGGTGCCGACCACT Exon 3
7 F1a ACCTTCGCTTACAGCCCG Exon 5 84.21 —
R1a CCTCACCTGTGACAGAAACAG Exon 5
2DL5 8 F1a GCGCTGTGGTGCCTCG Exon 3 82.19 —
R1a GACCACTCAATGGGGGAGC Exon 3
9 F1a TGCAGCTCCAGGAGCTCA Exon 5 83.09 —
R1a GGGTCTGACCACTCATAGGGT Exon 5
2DS1 10 F1b TCTCCATCAGTCGCATGAG Exon 4 79.34 —
F2b TCTCCATCAGTCGCATGAA Exon 4
Rb GGTCACTGGGAGCTGAC Exon 4
2DS2 11 F1a TTCTGCACAGAGAGGGGAAGTA Exon 4 80.55 —
R1a GGGTCACTGGGAGCTGACAA Exon 4
12 F1a CGGGCCCCACGGTTT Exon 5 83.47 KIR2DS2*00104
R1a GGTCACTCGAGTTTGACCACTCA Exon 5
2DS3 13 F1c AAACCTTCTCTCTCAGCCCA Exon 5 84.07 —
R1b GCATCTGTAGGTTCCTCCT Exon 5
14 F1a CTATGACATGTACCATCTATCCAC Exon 5 83.07 —
R1a AAGCAGTGGGTCACTTGAC Exon 5
2DS4 15 F1a CTGGCCCTCCCAGGTCA Exon 4 80.83 —
R1a TCTGTAGGTTCCTGCAAGGACAG Exon 4
16 F1a GTTCAGGCAGGAGAGAAT Exon 5 84.35 —
R1a GTTTGACCACTCGTAGGGAGC Exon 5
2DS5 17 F1a TGATGGGGTCTCCAAGGG Exon 4 81.54 KIR2DS5*003
R1a TCCAGAGGGTCACTGGGC Exon 4
18 F1a ACAGAGAGGGGACGTTTAACC Exon 4 82.18 —
R1a ATGTCCAGAGGGTCACTGGG Exon 4
2DP1 19 F1a GTCTGCCTGGCCCAGCT Exon 3 80.67 —
R1a GTGTGAACCCCGACATCTGTAC Exon 3
20 F1a CCATCGGTCCCATGATGG Exon 4 79.28 —
R1a CACTGGGAGCTGACAACTGATG Exon 4
3DL1 21 F1a CGCTGTGGTGCCTCGA Exon 3 79.62 KIR3DL1*009, *042, *057
R1a GGTGTGAACCCCGACATG Exon 3
22 F1b CCATCGGTCCCATGATGCT Exon 4 79.13 —
F2b CCATT GGTCCCATGATGCT Exon 4
F3b TCCATCGGTCCCATGATGTT Exon 4
Rb CCACGATGTCCAGGGGA Exon 4
3DL2 23 F1a CAAACCCTTCCTGTCTGCCC Exon 3 82.94 KIR3DL2*013, *014
R1a GTGCCGACCACCCAGTGA Exon 3
24 F1a CCCATGAACGTAGGCTCCG Exon 5 83.70 KIR3DL2*018
R1a CACACGCAGGGCAGGG Exon 5
3DL3 25 F1a GTCAGGACAAGCCCTTCCTC Exon 3 82.32 —
R1a GAGTGTGGGTGTGAACTGCA Exon 3
26 F1a TTCTGCACAGAGAGGGGATCA Exon 4 82.47 —
R1a GAGCCGACAACTCATAGGGTA Exon 4
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no. Primers Sequences (5′ –3′)
Primer
binding site Product Tm (
◦C) Alleles not detected
3DS1 27 F1a AGCCTGCAGGGAACAGAAG Exon 8 81.41 —
R1a GCCTGACTGTGGTGCTCG 3′UTR
28 F1b CATCGGTTCCATGATGCG Exon 4 80.38 —
F2b CATCAGTTCCATGATGCG Exon 4
Rb CCACGATGTCCAGGGGA Exon 4
3DP1 29 Fb GTACGTCACCCTCCCATGATGTA 5′UTR 85.97 KIR3DP1*004, *009002
Rb GAAAACGGTGTTTCGGAATAC Exon 3
GALC (control) 30 Fc TTACCCAGAGCCCTATCGTTCT 74.89 —
Rc GTCTGCCCATCACCACCTATT
GALC, galactosylceramidase; KIR, killer-cell immunoglobulin-like receptor; PCR, polymerase chain reaction; UTR, untranslated region.
aPrimers designed by Martin and Carrington (16).
bPrimers designed by Vilches et al. (23).






















































Figure 1 (A) Melt curve analysis of killer immunoglobulin-like receptor (KIR)-polymerase chain reaction (PCR) products melting to the right of the
internal control galactosylceramidase (GALC) (74.89◦C) and (B) KIR-ligand PCR amplicons melting to the right of the internal control albumin (ALB)
(75.62◦C).
99.1% (218/220) of individuals tested. All KIR-ligand primer
sets, except HLA-B Bw4:T80A81, were 100% concordant with
SBT results (Table 4). Our assay failed to correctly assign
HLA-B*38:02 to the Bw4:T80A81 allotype for two DNA
samples obtained from the IHWG database. The sample was
retyped by SBT and confirmed to be correctly assigned based
on exon 2, 3 and 4 sequences. In addition, the genomic
sequences for HLA-B*38:02:01, B*38:02:02 and B*38:02:03
were available to confirm that the reverse primer binding
site had no changes. SBT typing does not include the 5′
untranslated region (5′UTR); however, genomic sequences
were available for HLA-B*38:01:01, B*38:02:01 and B*38:14
and confirmed that the forward primer was conserved except
for a −7 mismatch. It is unlikely that this was the cause of
a failed PCR amplification as the forward primer was found
to successfully amplify other HLA-B alleles with the same
mismatch. It is therefore possible that these two samples
are undescribed B*38:02 alleles with changes in the 5′UTR.
Nevertheless, the HLA-B*38:02 allele is prevalent at a low
frequency in people of Taiwanese/Chinese descent (0.11% and
0.08%, respectively) and has not been reported within the
African continent (28).
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Table 2 PCR primer sets used for real-time PCR KIR-ligand genotyping assay
Gene Primers Sequences (5′ –3′)a Product Tm (◦C) Reference
HLA-A Bw4:I80 F CCATTGGGTGTCGGGTTTC[C] 87.39 This study
Rb CTCTGGTTGTAGTAGCGGAGCGCG[A]
Non-Bw4:T80 F AATCAGTGTCGTCGCGGTC[G] 87.65
R TGTAGTAGCCGCGCAGG[G]
HLA-B Bw6:N80 F TCAGCGTCGCCGGGGTCCC[A] 87.73 This study
R TGTAGTAGCCGCGCAGG[T]
Bw4:I80 F ACCCGGACTCAGAATCTCC[T] 87.96
Rb CTCTGGTTGTAGTAGCGGAGCGCG[A]
Bw4:T80A81 F ACCCGGACTCAGAATCTCC[T] 88.08
R TGTAGTAGCGGAGCGCG[G]
Bw4:T80L81 F ACCCGGACTCAGAATCTCC[T] 87.73
R CTCTGGTTGTAGTAGCGGAGCAGG[G]
HLA-C C1:N80 F AGCCAATCAGCGTCTCCGC[A] 88.34 This study
R GCTCTGGTTGTAGTAGCCGCGCAG[G]
C2:K80 F CCATTGGGTGTCGGGTTCT[A] 88.06
R GCTCTGGTTGTAGTAGCCGCGCAG[T]
ALB (control) F TCGATGAGAAAACGCCAGTAA 75.62 (26)
R ATGGTCGCCTGTTCACCAA
ALB, albumin; HLA, human leukocyte antigen; KIR, killer-cell immunoglobulin-like receptor; PCR, polymerase chain reaction.
a3′ Locked nucleic acid bases are depicted between square brackets. Melting temperature (Tm) for each PCR product was determined automatically
following melt curve analysis.
bThe same reverse primer is used for detection of HLA-A and -B Bw4:I80 alleles.
Table 3 Validation of real-time PCR KIR genotyping assay (n = 50)a
Carriers/noncarriers
KIR genes SSP KIR PCR Real-time KIR assay Concordant (%)
2DL1 48/2 48/2 100
2DL2 27/23 27/23 100
2DL3 41/9 41/9 100
2DL4 50/0 50/0 100
2DL5 26/24 26/24 100
2DS1 15/35 15/35 100
2DS2 27/23 27/23 100
2DS3 10/40 10/40 100
2DS4 47/7 47/7 100
2DS5 21/29 21/29 100
2DP1 48/2 48/2 100
3DL1 47/3 47/3 100
3DL2 50/0 50/0 100
3DL3 50/0 50/0 100
3DS1 13/37 13/37 100
3DP1 50/0 50/0 100
KIR, killer-cell immunoglobulin-like receptor; PCR, polymerase chain
reaction; SSP, sequence-specific primer.
aConcordance between assays was established by directly comparing
the number of individuals who did/did not carry the KIR gene divided by
the KIR genes present/absent x 100.
KIR genotyping in a South African population group
KIR genotyping using the real-time PCR KIR assay showed
similar gene frequencies to other South African population
groups studied (29, 30). We identified 20 different KIR
genotype profiles (Table 5), 2 of which have not been
previously reported (Bx46 and Bx70 ) and 1 undescribed KIR







KIR-ligand assay Concordant (%)
HLA-A Bw4:I80 62/158 62/158 100
Non-Bw4:T80 215/5 215/5 100
HLA-B Bw6:N80 180/40 180/40 100
Bw4:I80 93/127 93/127 100
Bw4:T80A81 49/171 47/171 95.9
Bw4:T80L81 11/209 11/209 100
HLA-C C1:N80 173/47 173/47 100
C2:K80 161/59 161/59 100
HLA, human leukocyte antigen; KIR, killer-cell immunoglobulin-like
receptor; PCR, polymerase chain reaction; SBT, sequence-based typing;
SSP, sequence-specific primer.
aConcordance between assays was established by directly comparing
the number of individuals who did/did not carry the KIR-ligand gene
divided by the KIR-ligand genes present/absent × 100.
Bx genotype with all KIR genes present with the exception of
KIR2DL2, KIR2DL3, KIR2DS1, KIR2DS2 and KIR3DS1.
KIR-ligand genotyping in a South African population
group
Using the real-time PCR KIR-ligand assay, we deter-
mined the absence/presence of the HLA-A/B Bw4 and
HLA-C C1/C2 motifs. At the HLA-A locus, 2.5% of
individuals were homozygous for Bw4:I80 (ligands for
KIR3DL1/S1), 69.1% were homozygous for non-Bw4:T80
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Table 5 Real-time PCR KIR genotyping in a South African Cohort (n = 81)a
KIR, killer-cell immunoglobulin-like receptor; PCR, polymerase chain reaction.
aFrequency of each KIR gene is expressed as a percentage and is defined as the number of individuals having the gene divided by the number of
individuals in the cohort (n = 81). Genotype frequency is defined by the number of individuals having a particular genotype divided by the number of
individuals within the cohort. The black boxes indicate the presence of the gene, whereas the open boxes indicate the absence of the gene. Bx* is a
new KIR genotype that has not been reported.
and the remaining 28.4% were heterozygotes (Figure 2).
At the HLA-B locus, 40.7% of individuals were Bw6:N80
homozygous. Of the remainder who carried a Bw4 allele
(ligands for KIR3DL1/S1), 48.1% were heterozygous for
Bw6:N80/Bw4:I80, 3.7% were Bw4:I80/T80A81 heterozygotes
and 7% were Bw4:I80 homozygotes. The Bw4:I80/T80L81
was detected in 1.2% of individuals, while no Bw4:T80L81
homozygotes or Bw4:T80L81/Bw6:N80 heterozygotes were
detected in this population. At the HLA-C locus, 16% of indi-
viduals were homozygous for C1:N80, 38% were homozygous
for C2:K80 and the remaining 46% were heterozygotes.
KIR/KIR-ligand pairs in a South African population
group
KIR and KIR-ligand data, when taken together, allow
receptor-ligand combinations to be determined (Table 6).
Within this relatively small South African cohort (n = 81),
the frequency of activating KIR/KIR-ligand pairs was lower
than that of the inhibitory KIR/KIR-ligand pairs. Activat-
ing KIR2DS1 paired with the HLA-C C2 ligand was found
at a frequency of 16% and KIR3DS1 paired with the puta-
tive HLA-B Bw4 ligand was present in 6.2% of individuals.
Inhibitory KIR genes (KIR2DL1/2/3 and KIR3DL1 ) and their
ligands HLA-C C2, HLA-C C1, HLA-C C1 and HLA-A/B
Bw4 were present at frequencies of 84%, 44%, 44% and 58%,
respectively.
Discussion
We have developed a fast and effective tool to determine KIR
and KIR-ligand profiles using real-time PCR and SYBR
Green chemistry. Our KIR and KIR-ligand assays were
validated against commercial and published methods and
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Figure 2 Frequency of killer immunoglobulin-like receptor (KIR)-ligand allele combinations in a South African Cohort (n = 81). On the basis of allelic
discrimination at codon 80, the KIR-ligand assay can identify the presence/absence of KIR-ligands human leukocyte antigen (HLA)-A (Bw4:I80 and
non-Bw4:T80) and HLA-B (Bw4:I80, Bw4:T80A81, Bw4:T80L81 and Bw6:N80) and HLA-C (C1 and C2).















ry 2DL1 81 (100) C2 68 (84) 68 (84.0)
2DL2 56 (69) C1 51 (63) 36 (44.4)
2DL3 60 (74) C1 51 (63) 36 (44.4)







2DS1 19 (23) C2 68 (84) 13 (16.0)
3DS1 10 (12) Bw4b 58 (72) 5 (6.2)
KIR, killer-cell immunoglobulin-like receptor.
aFrequency of each KIR/KIR-ligand combination is expressed as a
percentage and defined as the number of individuals having the paired
KIR/KIR-ligand (N) divided by the number of individuals within the cohort
(n = 81).
bPutative KIR-ligand for KIR3DS1 based on homology to KIR3DL1.
were found to be 100% and 99.1% concordant, respectively.
The advantage of our assays compared to the commercial
gel-based KIR SSP-PCR and HLA SBT methods, as well
as published KIR/KIR-ligand typing methods, includes its
low input DNA concentration, simple technique and ease of
interpretation of results. To enhance detection of KIR genes
that may contain sequence variation in the primer binding
sites, multiple primers were used for all except three genes
(Table 1). In addition, each of the assays uses a single internal
positive control gene with a melting peak significantly lower
than the KIR and KIR-ligand amplicon melting peaks. This
enables proper discrimination between the absence of a target
gene and a failed PCR. Most importantly, the KIR and
KIR-ligand assays are very cost-effective, costing as little
as 15%–20% of the price of commercial KIR and SBT
typing kits, provided the users have access to a real-time PCR
instrument. However, with respect to the HLA SBT typing
one must keep in mind the level of allele-specific detail that
sequencing provides as opposed to the real-time KIR-ligand
allotype designations (HLA-A/B Bw4 and HLA-C C1/C2 ).
Our assay is a single-round detection using SYBR Green
chemistry and melting curve analysis, which is cheaper and
simpler than other real-time PCR methods that make use of
fluorescent probes and multiple amplification steps (22).
Limitations of the KIR and KIR-ligand assay designs
are that due to the large number of KIR and HLA genes
described and allelic variation within these, certain alleles
can be either undetected or misclassified. The KIR primers
used detect all known allelic variants, except the pseudogene
KIR3DP1 primer set which does not detect KIR3DP1*004
and KIR3DP1*00902. The KIR-ligand assay failed to detect
HLA-B*38:02 as a Bw4:T80A81 allotype, but was not likely
due to a primer mismatch. Furthermore, the KIR-ligand
primers were designed to discriminate Bw4 from Bw6 at
codon 80. By definition, amino-acid residues at positions 77
and 80-83 are important in defining the Bw4 (NXXIALR,
NXXTALR, SXXIALR, DXXTLLR and SXXTLLR) and
Bw6 (SXXNLRG and GXXNLRG) amino-acid motifs (14,
31). Therefore, a limitation of our approach is that unclassi-
fied HLA-B alleles such as HLA-B*44:11, B*51:50, B*57:08
and HLA-A*24:61 that contain amino-acid changes within
the Bw4 motifs will be classified as Bw4. Likewise, unclassi-
fied HLA-B alleles such as HLA-B*07:11, B*07:57, B*08:17,
B*35:56, B*39:20, B*40:37, B*55:12, B*78:06, B*95:35,
B*08:29, B*27:42, B*037:05, B*25:52, B*37:14, B*47:03,
B*40:76 and B*41:05 that have amino-acid changes that are
divergent from the Bw6 motifs will be classified as Bw6.
Lastly, a number of HLA-B alleles encode the C1 amino-
acid motif (B*07:13, B*07:15, B*08:15, B*15:57, B*18:06,
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B*35:74, B*39:27, B*40:73, B*46:01-18, B*55:03, B*67:02
and B*73:01) and will be misclassified as Bw6 allotypes
by our assay. Therefore, complimentary HLA typing would
be necessary in the geographic areas where these alleles
have high frequencies, such as HLA-B*46 in Asia. Like-
wise for KIR2DS4 ligand identification, which consists of
HLA-A*11:01/02 and a subset of HLA-C alleles, further HLA
typing would be necessary.
When applied to a small South African sample set, we
found similar KIR gene frequencies to other published stud-
ies (29, 30), and identified an unreported KIR genotype profile
(with all KIR genes present with the exception of KIR2DL2,
KIR2DL3, KIR2DS1, KIR2DS2 and KIR3DS1 ). In addition,
paired KIR and KIR-ligand combinations could be determined
showing a dominance of inhibitory compared to stimulatory
KIR receptor pairings. Specific combinations of HLA and
KIRs have been associated with higher risk for autoimmune
disease (32, 33) and differential risk for certain infectious
diseases (17, 19), thus it remains to be seen how the repre-
sentation of activating/inhibitory KIR genes and their ligand
pairs might impact on disease susceptibility/resistance in our
population.
Conventional KIR and HLA genotyping methodologies
involve gel-based SSP-PCR and SBT methods, respectively.
These methods can be expensive, labor intensive and time-
consuming. We describe an optimized and validated real-time
PCR-based KIR and KIR-ligand assays that show high con-
cordance with commercial KIR and HLA typing methods.
Melt curve analysis offers straightforward determination of
the presence/absence of KIRs or known HLA ligands for
KIRs, thereby generating results much faster than conven-
tional methods. In addition, the assay is inexpensive and
allows for high-throughput data generation. Together, these
two assays have relevance to understanding NK cell function
in disease as well as in complications with pregnancy or bone
marrow transplantation.
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